Overview

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Status:
Terminated

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the tolerability and safety of rituximab in combination with methotrexate (MTX) and etanercept or adalimumab in participants with active rheumatoid arthritis (RA). The secondary objective was to explore the efficacy of rituximab in combination with MTX and etanercept or adalimumab in participants with active RA.

Phase:

Phase 2

Details

Lead Sponsor:

Biogen

Collaborators:

Genentech, Inc.
Hoffmann-La Roche

Treatments:

Adalimumab
Etanercept
Folic Acid
Methotrexate
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rituximab
Vitamin B Complex